Mixed reviews for Vioxx successor
13th Nov 2006, 18:09 GMT
The first published studies of Arcoxia, the drug that Merck & Co. hopes will take the place of its withdrawn painkiller Vioxx, are getting mixed reviews from doctors, some of whom say the results do not make a case for the medication’s approval.
Mixed reviews for Vioxx successor related news:
- Vioxx-Like Drug Gets Mixed Reviews — Dayton Daily News National Headlines
- Merck's Vioxx Replacement Gets Mixed Reviews — MedicineNet Chronic Pain General
- Merck's Arcoxia Draws Mixed Reviews — WSJ.com: US Business
- Results on Merck's new painkiller draw mixed reviews — azcentral.com | business
- Docs Give Merck Painkiller Acroxia Mixed Reviews — FOXNews.com
- Vioxx successor poses heart risk in study — Boston Globe -- Business News
- Results Mixed on Merck's New Painkiller — LancasterOnline - Health
- Results mixed on Merck's new painkiller (AP) — Yahoo! News: Health News
- Results mixed on Merck's new painkiller (Associated Press) — Yahoo! Health: Health News
- Tests of new Merck painkiller criticized — baltimoresun.com - health & science
Latest news from MSNBC.com: Health:
- Hospitals race to improve heart attack care
- Diabetes drug may cut heart risks
- U.S. kids getting hardened arteries
- Red meat raises breast cancer risk
- Genes may determine who survives trauma
- Drug-covered balloon to open arteries?
- Tamiflu takers: Watch out for bizarre behavior
- Backlash from too much flu vaccine?
- Diseased gums raise risk of pancreatic cancer
- Blow to chest can be fatal in child athletes